WO2007056213A2 - Drug-eluting stents coated with p2y12 receptor antagonist compound - Google Patents

Drug-eluting stents coated with p2y12 receptor antagonist compound Download PDF

Info

Publication number
WO2007056213A2
WO2007056213A2 PCT/US2006/043085 US2006043085W WO2007056213A2 WO 2007056213 A2 WO2007056213 A2 WO 2007056213A2 US 2006043085 W US2006043085 W US 2006043085W WO 2007056213 A2 WO2007056213 A2 WO 2007056213A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
acetal
formula
receptor antagonist
substituted
Prior art date
Application number
PCT/US2006/043085
Other languages
English (en)
French (fr)
Other versions
WO2007056213A3 (en
Inventor
José L. BOYER
James G. Douglass, Iii
Sammy R. Shaver
Original Assignee
Inspire Pharmaceuticals, Inc.
University Of North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals, Inc., University Of North Carolina filed Critical Inspire Pharmaceuticals, Inc.
Priority to JP2008539086A priority Critical patent/JP2009514604A/ja
Priority to EP06836933A priority patent/EP1942910A2/en
Publication of WO2007056213A2 publication Critical patent/WO2007056213A2/en
Publication of WO2007056213A3 publication Critical patent/WO2007056213A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
PCT/US2006/043085 2005-11-04 2006-11-02 Drug-eluting stents coated with p2y12 receptor antagonist compound WO2007056213A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2008539086A JP2009514604A (ja) 2005-11-04 2006-11-02 Ｐ２ｙ１２受容体アンタゴニスト化合物でコートされた薬剤溶出ステント
EP06836933A EP1942910A2 (en) 2005-11-04 2006-11-02 Drug-eluting stents coated with p2y12 receptor antagonist compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/267,834 US7452870B2 (en) 2000-08-21 2005-11-04 Drug-eluting stents coated with P2Y12 receptor antagonist compound
US11/267,834 2005-11-04

Publications (2)

Publication Number Publication Date
WO2007056213A2 true WO2007056213A2 (en) 2007-05-18
WO2007056213A3 WO2007056213A3 (en) 2009-04-30

Family

ID=38023857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/043085 WO2007056213A2 (en) 2005-11-04 2006-11-02 Drug-eluting stents coated with p2y12 receptor antagonist compound

Country Status (4)

Country Link
US (2) US7452870B2 (US07618949-20091117-C00004.png)
EP (1) EP1942910A2 (US07618949-20091117-C00004.png)
JP (1) JP2009514604A (US07618949-20091117-C00004.png)
WO (1) WO2007056213A2 (US07618949-20091117-C00004.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618949B2 (en) 2000-08-21 2009-11-17 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006204159A1 (en) * 2005-01-06 2006-07-13 Astrazeneca Ab Novel pyridine compounds
JP2008537745A (ja) * 2005-03-30 2008-09-25 インスパイアー ファーマシューティカルズ，インコーポレイティド ４，６−二置換−テトラヒドロ−フロ、チエノ、ピロロ及びシクロペンタ−［３，４］［１，３］ジオキソールの調製のための方法
US20080312208A1 (en) * 2005-07-13 2008-12-18 Astrazeneca Ab Pyridine Analogues
TW200815426A (en) * 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
EP2041115A4 (en) * 2006-07-04 2010-07-07 Astrazeneca Ab NEW PYRIDINE ANALOG
CN101511792A (zh) * 2006-07-04 2009-08-19 阿斯利康(瑞典)有限公司 新的吡啶类似物
TW200811133A (en) * 2006-07-04 2008-03-01 Astrazeneca Ab New pyridine analogues III 334
WO2008004941A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab New pyridine analogues
EP2076210A2 (en) * 2006-10-24 2009-07-08 Paul Zamecnik Medical device coatings and coated stents
TW200833333A (en) * 2007-01-12 2008-08-16 Astrazeneca Ab New pyridine analogues
EP2111400A4 (en) * 2007-01-12 2010-07-07 Astrazeneca Ab Pyridine compounds and their use as P2Y12 antagonists
CL2008000093A1 (es) * 2007-01-12 2008-08-22 Astrazeneca Ab Compuestos derivados de piridina, inhibidores de p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de un desorden de agregacion plaquetaria.
PE20081892A1 (es) * 2007-07-13 2009-02-21 Astrazeneca Ab Nuevos analogos de amino-piridina como agentes antitromboticos
EP2153833A1 (en) * 2008-08-14 2010-02-17 Royal College of Surgeons in Ireland ADP-receptor antagonist for treatment of inflammatory disease
US20100286765A1 (en) * 2009-05-07 2010-11-11 Paul Zamecnik Medical Device Coatings and Coated Stents
US8609066B2 (en) * 2009-08-10 2013-12-17 Jaya Brigitte Rosenmeier Use of UTP for the diagnosis of stenoses and other conditions of restricted blood flow
US10307292B2 (en) 2011-07-18 2019-06-04 Mor Research Applications Ltd Device for adjusting the intraocular pressure
WO2013033178A1 (en) 2011-08-30 2013-03-07 University Of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
US9388127B2 (en) 2012-04-17 2016-07-12 University College Dublin, National University Of Ireland, Dublin Thromboxane receptor antagonists
US9718781B2 (en) 2012-04-17 2017-08-01 University College Dublin, National University Of Ireland, Dublin Methods and compounds for treating proliferative disorders and viral infections
WO2015153401A1 (en) * 2014-04-04 2015-10-08 Merck Sharp & Dohme Corp Phosphate based linkers for intracellular delivery of drug conjugates
EP3310756B1 (en) 2015-06-16 2020-12-09 ATXA Therapeutics Limited Thromboxane receptor antagonists
US10800826B2 (en) 2015-10-05 2020-10-13 Merck Sharp & Dohme Corp. Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
US11510993B2 (en) 2015-10-06 2022-11-29 Merck Sharp & Dohme Llc Antibody drug conjugate for anti-inflammatory applications
WO2017132103A2 (en) 2016-01-29 2017-08-03 Merck Sharp & Dohme Corp. Phosphonate linkers and their use to facilitate cellular retention of compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233062A1 (en) * 1999-09-03 2005-10-20 Hossainy Syed F Thermal treatment of an implantable medical device

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US732408A (en) * 1902-09-17 1903-06-30 William F Hanson Machine for molding crayons.
US3321462A (en) * 1963-07-15 1967-05-23 Syntex Corp Process for the preparation of nucleoside polyphosphates
GB1407903A (en) 1973-03-21 1975-10-01 Ici Ltd Nucleotide derivatives
DE2934746A1 (de) 1979-08-28 1981-03-19 A. Nattermann & Cie GmbH, 5000 Köln Oxoimidazolinalkansaeuren, deren salze und ester sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
JPS5973524A (ja) * 1982-10-21 1984-04-25 Meito Sangyo Kk 血栓性疾患処置剤
WO1989004321A1 (en) 1987-11-05 1989-05-18 The Worcester Foundation For Experimental Biology Diadenosine 5', 5'''-p1, p4-tetraphosphate and analogs thereof as antithrombotic agents
US5049550A (en) * 1987-11-05 1991-09-17 Worcester Foundation For Experimental Biology Diadenosine 5', 5'"-p1, p4,-tetraphosphate analogs as antithrombotic agents
US5635180A (en) * 1988-02-17 1997-06-03 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
GB9015684D0 (en) 1990-07-17 1990-09-05 Medical Res Council Synthesis and uses of spin labelled ribonucleosides and ribonucleotides
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
US5654285A (en) * 1991-04-06 1997-08-05 Astra Pharmaceuticals Limited ADP and ATP analogues, process for making and administration to inhibit ADP-induced platelet aggregation
ES2078654T3 (es) 1991-04-06 1995-12-16 Astra Pharma Prod Analogos de atp.
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
ES2108425T3 (es) 1993-02-10 1997-12-16 Astra Pharma Prod Analogos de atp sustituidos con n-alquilo-2.
WO1995010538A1 (en) 1993-10-15 1995-04-20 The University Of North Carolina At Chapel Hill Dna encoding the human p2u receptor and null cells expressing p2u receptors
US5814609A (en) * 1993-10-22 1998-09-29 University Of Southern California Compositions containing a disintegrin and methods for its use in preventing metastasis and other conditions
US5656256A (en) 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
EP0796098A4 (en) * 1994-12-22 1998-04-29 Smithkline Beecham Corp FIBRINOGEN RECEPTOR ANTAGONISTS
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
EP0840740B1 (en) 1995-07-11 2002-05-02 AstraZeneca AB New inhibitors of platelet aggregation
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
JP3519199B2 (ja) 1996-02-06 2004-04-12 株式会社ソニー・コンピュータエンタテインメント 画像生成装置
CN1229114C (zh) 1996-03-27 2005-11-30 印斯拜尔药品股份有限公司 用三磷酸尿苷和相关化合物治疗纤毛运动障碍的方法
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5681823A (en) * 1996-05-02 1997-10-28 Prp Inc. P1, P4 -dithio-P2 -P3 -monochloromethylene 5', 5'"-diadenosine P1, P4 -tetraphosphate as antithrombotic agent
US5789391A (en) 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US5968913A (en) 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US5962432A (en) 1996-07-03 1999-10-05 Inspire Pharmaceuticals, Inc. Sterilized, isotonic and pH-adjusted pharmaceutical formulation of uridine triphosphate
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
WO1998015835A1 (en) 1996-10-08 1998-04-16 Inspire Pharmaceuticals, Inc. Method of early lung cancer detection via sputum induction and analysis of sputum to detect cancer associated substances
US6159952A (en) 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds
WO1998028300A1 (en) 1996-12-20 1998-07-02 Astra Pharmaceuticals Ltd. Triazolo[4,5-d]pyrimidinyl derivatives and their use as medicaments
DK0981534T3 (da) * 1997-02-06 2006-09-04 Inspire Pharmaceuticals Inc Dinukleotider og deres anvendelser
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
SE9702774D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
JP3723227B2 (ja) 1997-07-25 2005-12-07 インスパイアー ファーマシューティカルズ，インコーポレイティド ジ（ウリジン５’）−テトラホスフェート及びその塩の大規模生産のための方法
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
ZA987847B (en) 1997-08-29 1999-06-28 Univ North Carolina Method of treating lung diseases with uridine 5'-diphosphate and analogs thereof
US6528640B1 (en) * 1997-11-05 2003-03-04 Ribozyme Pharmaceuticals, Incorporated Synthetic ribonucleic acids with RNAse activity
EP1087777B1 (en) * 1998-05-22 2003-02-19 Inspire Pharmaceuticals, Inc. Therapeutic dinucleotide and derivatives
SE9804175D0 (sv) 1998-12-02 1998-12-02 Astra Pharma Prod New assay
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
WO2000039145A1 (en) 1998-12-23 2000-07-06 The University Of North Carolina At Chapel Hill Targeted gene transfer using g protein coupled receptors
CA2359891A1 (en) 1999-02-26 2000-08-31 Inspire Pharmaceuticals, Inc. Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof
SE9903290D0 (sv) 1999-09-15 1999-09-15 Astra Pharma Prod Novel compounds
SE9904129D0 (sv) 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904377D0 (sv) 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
US6908624B2 (en) * 1999-12-23 2005-06-21 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US6654285B1 (en) * 2002-02-27 2003-11-25 Advanced Micro Devices, Inc. Method of matching core cell and reference cell source resistances
US7368438B2 (en) 2003-10-21 2008-05-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for inhibiting platelet aggregation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233062A1 (en) * 1999-09-03 2005-10-20 Hossainy Syed F Thermal treatment of an implantable medical device

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
'3rd International Meeting, ADP 2004', 06 September 2004 article BOYER ET AL.: 'Development of Reversible P2Y12 receptor antagonists.' *
ABBRACCHIO ET AL.: 'International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy.' PHARMACOL REV vol. 58, no. 3, September 2006, pages 281 - 341, XP008127061 *
CONLEY ET AL.: 'Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis.' CURRENT OPINION IN HEMATOLOGY 2003 vol. 10, no. 333338, September 2003, page 333, XP009061394 *
KAUFFENSTEIN ET AL.: 'Adenine triphosphate nucleotides are antagonists at the P2Y12 2 Receptor.' J THROMB HAEMOST vol. 2, November 2004, page 19801988, XP008127060 *
PINTOR ET AL.: 'Diadenosine polyphosphates in the central nervous system.' NEUROSCIENCE RESEARCH COMMUNICATIONS vol. 20, no. 2, 20 December 1996, pages 69 - 54, XP008127058 *
'Poster presented at the 4th International Symposium of Nucleosides and Nucleotides Purines 2004 Meeting, 06-09 June 2004 (06.06.2004)', 06 June 2004 article DOUGLASS ET AL.: 'Effects of ribose modified adenosine phosphates in models of acute and inflammatory pain.', page 1, XP008127059 *
'SEMINARS IN THROMBOSIS AND HEMOSTASIS', vol. 31, April 2005 article JACOBSON ET AL.: 'Molecular Recognition at Adenine Nucleotide (P2) Receptors in Platelets.' *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618949B2 (en) 2000-08-21 2009-11-17 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound

Also Published As

Publication number Publication date
US20060122143A1 (en) 2006-06-08
US20080287671A1 (en) 2008-11-20
EP1942910A2 (en) 2008-07-16
US7452870B2 (en) 2008-11-18
JP2009514604A (ja) 2009-04-09
US7618949B2 (en) 2009-11-17
WO2007056213A3 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
US7618949B2 (en) Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7101860B2 (en) Composition and method for inhibiting platelet aggregation
EP1758915A2 (en) Composition and method for inhibiting platelet aggregation
AU2001285470A1 (en) Composition and method for inhibiting platelet aggregation
US7749981B2 (en) Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7943760B2 (en) Non-nucleotide composition for inhibiting platelet aggregation
US7504497B2 (en) Orally bioavailable compounds and methods for inhibiting platelet aggregation
EP1685135B1 (en) TETRAHYDRO-FURO[3,4-d]DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION
WO2007140333A2 (en) Mononucleoside phosphonate compounds
US7932376B2 (en) Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
WO2007056217A2 (en) Drug-eluting stents coated with non-nucleotide p2y12 receptor antagonist compound
JP2009520510A (ja) 非ヌクレオチドｐ２ｙ１２受容体アンタゴニスト化合物でコーティングした薬剤溶出ステント

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006836933

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008539086

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE